Document is current

Article History

Received: 30 January 2024

Accepted: 31 July 2024

First Online: 19 August 2024

Declarations

:

: This study involved physicians providing their agreement on statements regarding the treatment of patients only and no patient data was utilized; therefore, institutional review board approval was not applicable. To maintain confidentiality, the physician responses were anonymized and aggregated for analysis. Participation in the survey was voluntary, and all participating physicians provided informed consent prior to their involvement.

: Not applicable.

: Marc Miravitlles has received speaker fees from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, GlaxoSmithKline, Menarini, Kamada, Takeda, Zambon, CSL Behring, Specialty Therapeutics, Janssen, Grifols, and Novartis, consulting fees from AstraZeneca, Atriva Therapeutics, Boehringer Ingelheim, BEAM Therapeutics, Chiesi, GlaxoSmithKline, CSL Behring, Inhibrx, Ferrer, Menarini, Mereo Biopharma, Spin Therapeutics, Specialty Therapeutics, ONO Pharma, Palobiofarma SL, Takeda, Novartis, Novo Nordisk, Sanofi, Zambon, and Grifols and research grants from Grifols. Alice M Turner has received either grants or speaker fees from AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, Chiesi, CSL Behring, Takeda, Vertex, and Grifols. Maria Sucena has received speaker fees from AstraZeneca Bial, Boehringer Ingelheim, CSL Behring, and Grifols, and consulting fees from Bial and CSL Behring. Jean-François Mornex has received consulting fees from CSL Behring, Grifols, LFB, and Takeda, payment or honoraria and support for attending meetings from CSL Behring, Grifols, and LFB, and is a member of the scientific board of ADAAT. Timm Greulich has received personal fees from AstraZeneca, Berlin-Chemie, Boehringer Ingelheim, Chiesi, CSL Behring, GlaxoSmithKline, and Novartis, and grants and personal fees from Grifols. Marion Wencker has received consulting fees from CSL Behring and GlaxoSmithKline, has received support for attending meetings from VisionHealth, and is the Chief Medical Officer for Sterna Biologicals. N. Gerrard McElvaney has received research grants and honoraria from Grifols, has received consulting fees from CSL Behring and Vertex, and has participated in an advisory board for Vertex.